Articles

March 30, 2026 Alnylam Named One of Fast Company's Most Innovative Companies for 2026 RNAi therapeutics pioneer has been recognized by Fast Company as one of the most innovative companies for the 3rd time and ranks #3 in the "Medicines and Therapeutics" category. Read More ›
March 27, 2026 Five Things to Know about TRITON-CM & How Community Insight is Shaping the Future of ATTR- ... TRITON-CM, Alnylam's Phase 3 clinical trial evaluating nucresiran, a third-generation investigational RNAi therapeutic for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), represents one of the largest global studies ever conducted in this disease. Read More ›
March 26, 2026 Alnylam Awarded 2026 Scientific Impact Award by MassBio Alnylam was recognized by Mass Bio for its pioneering work in RNA interference and the development of RNAi therapeutics as an innovative new class of medicines. Read More ›
February 12, 2026 Alnylam BioVenture Challenge: Supporting the Next Generation of Biotech Leaders The Alnylam BioVenture Challenge is a partnership with Nucleate designed to empower the next generation of biotech leaders. Discover how we're supporting bold scientific ideas to advance the future of medicine. Read More ›
January 21, 2026 Alnylam CEO Yvonne Greenstreet: What Leadership Has Taught Me Alnylam's CEO Yvonne Greenstreet on leadership lessons she's learned in her first five years as CEO and how those lessons are informing our next five year plan. Read More ›
January 21, 2026 Alnylam Recognized by Newsweek as One of America’s Most Responsible Companies for the Four ... Alnylam is proud to be recognized by Newsweek as one of America's Most Responsible Companies for 2026, our 4 year in a row. Read More ›
December 17, 2025 Alnylam Announces Major Expansion of U.S. Pharmaceutical Manufacturing Facility $250 million investment will add new capacity and siRNA enzymatic ligation capabilities to Alnylam's Norton, Massachusetts site Read More ›
December 8, 2025 The Future of Medicine is in Our Genes Additional human genetics data partnerships are helping scientists identify new drug targets, improving the chances of developing effective medicines Read More ›
December 3, 2025 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our Su ... We are extremely proud to be recognized once again as a Boston Globe Top Place to Work marking our 11th year in a row on the list. Read More ›
November 18, 2025 Alnylam Challengers: Empowering Frontline Care for Underserved Communities in Boston We are investing $2 million to advance the essential work of Boston’s frontline Care Navigators through Alnylam Challengers, our Read More ›
Subscribe to Articles